Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

GLP-1 injections, such as semaglutide and tirzepatide products like Ozempic, Wegovy, Mounjaro and Zepbound have led many consumers to spend significantly less money on food — both at grocery stores ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...